MD, Free University of Brussels
BA, Clark University

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety to Brivaracetam in subjects (>16 to 80 years old) with partial onset seizures
06/01/2011 - 05/31/2013 (PI)
UCB Biosciences Inc.

A Phase 3, open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of Protocol #1379
06/01/2011 - 05/31/2013 (PI)
UCB Biosciences Inc.

A Multi-Center, Open-Label, Long-Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures
12/13/2004 - 12/12/2007 (PI)
UCB, Inc.

Trileptal Pregnancy Registry
07/01/2006 - 06/30/2007 (PI)
Minnesota Epilepsy Group, P.A.

An Open-Label Extension Trial to Determine Safety and Efficacy of Long-Term Oral SPM 927 in Patients with Partial Seizures
10/06/2004 - 01/31/2007 (PI)
Schwarz Biosciences, Inc.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization
04/01/2004 - 03/30/2006 (PI)
Schwarz Biosciences, Inc.

A Multi-Center, Double-Blind, Randomized, Parallel-Group Evaluation of Lamictal Extended-Release Adjunctive Therapy In Patients with Primary Generalized Tonic-Clonic Seizures
12/10/2004 - 12/09/2005 (PI)
GlaxoSmithKline, Inc.

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age from
10/13/2004 - 10/12/2005 (PI)
UCB Pharma, Inc.

A Multi-Center, Double-Blind, Randomized, Parallel-Group Evaluation of Lamictal Extended-Release Adjunctive Therapy In Subjects With Partial Seizures
09/27/2004 - 09/26/2005 (PI)
GlaxoSmithKline, Inc.

An Open-Label Extension Trial to Determine Tolerability and Efficacy of Long-Term Oral SPM 927 as Adjunctive Therapy in Patients with Partial Seizures
11/01/2003 - 10/31/2004 (PI)
Schwarz Biosciences, Inc.

Showing 10 of 13 results. Show All Results

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray…
02/03/2016 - 02/28/2017 (PI)
Acorda Therapeutics, INC

Progesterone Therapy for Women with Epilepsy
02/01/2006 - 03/31/2007 (PI)
Beth Israel NIH-NINDS
5 R01 NS039466-05


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Stefanidou M, Montouris G. Reproductive and Sexual Health Concerns in Transition-Age Adolescents and Young Adults With Epilepsy. Semin Pediatr Neurol. 2020 Dec; 36:100855.View Related Profiles. PMID: 33308522
  2. Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, Chung S. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Epilepsy Behav. 2020 09; 110:107146. PMID: 32563898
  3. Scheuerle AE, Holmes LB, Albano JD, Badalamenti V, Battino D, Covington D, Harden C, Miller D, Montouris GD, Pantaleoni C, Thorp J, Tofighy A, Tomson T, Golembesky AK. Levetiracetam Pregnancy Registry: Final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. Birth Defects Res. 2019 08 01; 111(13):872-887. PMID: 31124321
  4. Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguère-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J. Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology. Curr Med Res Opin. 2019 08; 35(8):1415-1420. PMID: 30870597
  5. Reaven NL, Funk SE, Montouris GD, Saurer TB, Story TJ. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study. Epilepsy Behav. 2018 11; 88:66-73. PMID: 30241056
  6. Nuss S, Camayd-Muñoz C, Jonas R, Wenger JK, Sewell K, Montouris G, Douglass L. Defining the Virtual Patient-Centered Medical Home. Clin Pediatr (Phila). 2018 11; 57(13):1592-1596.View Related Profiles. PMID: 30111172
  7. Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. Epilepsy Behav. 2017 Aug; 73:46-50. PMID: 28609734
  8. Gidal BE, Wechsler RT, Sankar R, Montouris GD, White HS, Cloyd JC, Kane MC, Peng G, Tworek DM, Shen V, Isojarvi J. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology. 2016 Oct 25; 87(17):1806-1812. PMID: 27683846; PMCID: PMC5089527; DOI: 10.1212/WNL.0000000000003253;
  9. Piña-Garza JE, Chung S, Montouris GD, Radtke RA, Resnick T, Wechsler RT. Challenges in identifying Lennox-Gastaut syndrome in adults: A case series illustrating its changing nature. Epilepsy Behav Case Rep. 2016; 5:38-43. PMID: 26977407; PMCID: PMC4782006; DOI: 10.1016/j.ebcr.2016.01.004;
  10. Montouris G, Hohler AD. Cultural Barriers to Medication Adherence in Epilepsy. Continuum (Minneap Minn). 2016 Feb; 22(1 Epilepsy):266-9.View Related Profiles. PMID: 26844742; DOI: 10.1212/CON.0000000000000286;
Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Available to Mentor as: (Review Mentor Role Definitions):
  • Project Mentor
Contact for Mentoring: